1
Johnson Alan T, Kaneko Satoru, Mohan Raju, Oda Kozo, Schweiger Edwin J: Isoquinolinone derivatives and their use as therapeutic agents. X Ceptor Therapeutics, Sankyo Company, Johnson Alan T, Kaneko Satoru, Mohan Raju, Oda Kozo, Schweiger Edwin J, ROTH Carol J, July 15, 2004: WO/2004/058717 (47 worldwide citation)

This invention is directed to isoquinolinone derivatives and their use in modulating the activity of orphan nuclear receptors, pharmaceutical compositions containing such derivatives, and methods of using such derivatives in treating disease-states associated with nuclear receptor activity.


2
Tamaki Kazuhiko, Yamaguchi Takahiro, Oda Kozo, Terasaka Naoki, Nakai Daisuke, Nakadai Masakazu: (Ja) 2以上の置換基を有するベンゼン化合物, (En) Benzene compound having 2 or more substituents. Daiichi Sankyo Company, Tamaki Kazuhiko, Yamaguchi Takahiro, Oda Kozo, Terasaka Naoki, Nakai Daisuke, Nakadai Masakazu, YAGUCHI Toshiaki, May 4, 2006: WO/2006/046593 (45 worldwide citation)

(EN) Disclosed is an excellent LXR modulator. Specifically disclosed is a compound represented by the general formula (I) below or the like. (I) [In the formula, R1 represents a -COR9 (wherein R9 represents an alkyl, optionally substituted alkoxy or optionally substituted amino); R2 represents an H, ...


3
Arai Masami, Kaneko Satoru, Shibuya Satoshi, Watanabe Tsuyoshi, Oda Kozo: (Ja) 置換された縮環ピリミジン-4(3h)-オン化合物, (En) Substituted fused pyrimidine-4(3h)-one compound. Sankyo Company, X Ceptor Therapeutics, Arai Masami, Kaneko Satoru, Shibuya Satoshi, Watanabe Tsuyoshi, Oda Kozo, KUMAKURA Yoshio, March 17, 2005: WO/2005/023782 (10 worldwide citation)

(EN) A compound represented by the general formula (I): (I) [wherein A is phenyl, etc.; R1 is R1a (R1a is substituted alkyl, etc.), -Z1b-R1b (R1b is substituted alkyl, etc. and Z1b is -NH-, etc.), -Z1c-R1c (R1c has the same meaning as R1b or is alkyl and Z1c is -C≡C-, etc.), -N(R1b)(R1c), etc.; R2 a ...


4
Yoshida Akira, Oda Kozo, Ishihara Sadao, Kasai Takashi, Saito Fujio, Koike Hiroyuki, Koga Teiichiro, Kitazawa Eiichi, Kogen Hiroshi, Hayakawa Ichiro: Amide and urea derivatives having anti-hypercholesteremic activity, their preparation and their therapeutic uses.. Sankyo, January 4, 1995: EP0632036-A2 (3 worldwide citation)

Compounds of formula (I): in which: R is alkyl or a group of formula (II), (III), (IV) or (V): and in which the groups R, R, R and R are hydrogen or various organic groups; and pharmaceutically acceptable salts thereof are useful in the treatment and prophylaxis of hypercholesteremia and arterioscle ...


5
Tamaki Kazuhiko, Yamaguchi Takahiro, Oda Kozo, Terasaka Naoki, Nakai Daisuke, Nakadai Masakazu: Benzene compound having 2 or more substituents. Daiichi Sankyo, July 11, 2007: EP1806332-A1 (3 worldwide citation)

A superior LXR modulator is provided. A compound represented by the general formula (I): [wherein R 1 : -COR 9 (wherein R 9 : alkyl, optionally substituted alkoxy or optionally substituted amino); R 2 : H, OH, alkoxy, optionally substituted amino, etc.; R 3 : H, optionally substituted alkyl, cycloal ...


6
Yoshida Akira, Oda Kozo, Kasai Takashi, Koga Teiichiro, Hasegawa Kazuo: Tricyclic heterocyclic compound.. Sankyo, February 1, 1995: EP0636619-A1 (2 worldwide citation)

[Constitution] A tricyclic heterocyclic compound represented by general formula (I) wherein R and R represent each hydrogen, lower alkyl, lower alkoxy, halogen or halogenated lower alkyl; R represents hydrogen or lower alkyl; R represents substituted phenyl or naphthyl; R represents hydrogen or lowe ...


7
Yoshida Akira C O Sankyo Compa, Oda Kozo C O Sankyo Company Li: Process for preparing carbapenem and penem compounds and new compounds involved in that process.. Sankyo, March 16, 1994: EP0587436-A1 (1 worldwide citation)

Penem and carbapenem compounds having a group of formula -SA are prepared from a corresponding compound having a substituted thio, sulphinyl or sulphonyl group at this position by reaction with a compound ASH (where A is various organic groups) in the presence of a salt of a metal of Group II or III ...


8
Yoshida Akira, Oda Kozo, Kasai Takashi, Shimada Kousei, Kogen Hiroshi, Hayakawa Ichiro, Ishihara Sadao, Koga Teiichiro, Kitazawa Eiichi, Tokui Taro: Urea and amide derivatives having acat inhibitory activity, their preparation and their therapeutic and prophylactic use. Sankyo, March 19, 1997: EP0763524-A1 (1 worldwide citation)

Compounds of formula (I): wherein: R is alkyl; R, R, R and R are the same or different and each is hydrogen, optionally substituted alkyl or various other organic groups; R is alkyl; R is a group of formula (II), (III), (IV), (V), (VI), (VII), (VIII) or (IX): wherein: A is a single bond, alkylene or ...


9
Wakabayashi Kenji, Oda Kozo: Fluorescent labeled ligand. Sankyo, September 25, 2003: JP2003-267969 (1 worldwide citation)

PROBLEM TO BE SOLVED: To provide a simple and comprehensive method for testing an LXR- binding ability.SOLUTION: A compound represented by the general formula (I) (R1 and R2 are each independently H, a halogen, a 1 to 20C alkyl, or the like) or its salt.


10
Kaneko Satoru, Watanabe Tsuyoshi, Oda Kozo, Mohan Raju, Schweiger Edwin J, Martin Richard: Fused-ring pyrimidin-4(3h)-one derivatives, processes for the preparation and uses thereof. Sankyo Company, X Ceptor Therapeutics, Kaneko Satoru, Watanabe Tsuyoshi, Oda Kozo, Mohan Raju, Schweiger Edwin J, Martin Richard, NAKAMURA Minoru, December 24, 2003: WO/2003/106435 (1 worldwide citation)

AbstractNovel compounds of the following formula (I) and pharmacologically acceptable salt and esters thereof can modulate LXR function and as a result show excellent anti-arteriosclerotic and anti-inflammatory activity:wherein:A represents aryl or heteroaryl;R¿1?, R¿2? and R¿3? are the same or diff ...